Pierre Fabre
New ways to care  

The new Gustave Roussy International Prize, of which Pierre Fabre Laboratories is the major partner, will be awarded each year to a researcher whose work has demonstrated a major impact on the care of cancer patients. For its first edition, the Gustave Roussy Prize went to Prof. Charles Swanton, a pioneer in cancer research. It was awarded by Prof. Barlesi, Director of the Gustave Roussy institute, at a ceremony held on February 4 at the Théâtre du Lido in Paris, in the presence of leading figures from the scientific and academic worlds. Prof. Charles Swanton, Clinical Director of the Francis Crick Institute in London, has been recognized for his outstanding contributions to the understanding and treatment of cancer. His groundbreaking work has transformed precision medicine, influencing the care of millions of patients worldwide. His research has not only reshaped our understanding of tumor evolution and genomic instability but has also paved the way for new diagnostic and therapeutic strategies. As a major partner in this award, Pierre Fabre salutes the significant impact of his discoveries on diagnostic and treatment strategies in oncology. 

From January 12 to 16, Eric Ducournau and his team were present at the key event for pharmaceuticals, biotechs and healthcare investors. They took part in over 100 meetings with innovative companies, strategic partners and investors. By participating in this latest edition of the JP Morgan Healthcare Conference, Pierre Fabre has reaffirmed its commitment to becoming a global player in the field of innovative medicines. Open innovation at the heart of our growth strategy  More than fifteen partnerships with innovative companies have been signed since Pierre Fabre first took part in this key event for the pharmaceutical industry.   The company is pursuing its efforts to strengthen its position in the therapeutic areas of oncology, dermatology, urology and rare diseases. Discussions at JP Morgan will enable us to explore new opportunities in these fields at all stages of the product life cycle, from preclinical to market launch in the territories where Pierre Fabre operates commercially. Consolidating partnerships for the future Exchanges with several of our long-standing partners have also enabled us to consolidate our collaborations. The JP Morgan Conference is an opportunity for us to take stock of our progress and consider the next steps in our R&D and commercial development. The team present had the opportunity to exchange views with Atara, originator of a cell therapy marketed in Europe; Pfizer, our partner in targeted therapies; Abbvie; and Scorpion Therapeutics, co-development partner in several oncology clinical programs.

The script of the video. •    Could you please introduce yourself? Hello, my name is Jerry Liu. I’m 37 years old. I’ve been with Pierre Fabre Taiwan as MSL for four months. The area I’m responsible for is BRAF-mutant solid tumors. •    What is your professional background before being an MSL?  I have a PhD in Immunology. So, I'm familiar with autoimmune diseases like SLE (Systemic Lupus Erythematosus). Before joining Pierre Fabre, I worked at a genetic testing company providing services for cancer patients. It equips me with knowledge of molecular biology, and disease background for solid tumors. •    How would you define the MSL role? The key mission of MSL is adapting the development of new drugs or indications to the clinical practice of patient treatment. •    What do you like about being an MSL? I have the chance to deliver medical information to clinicians, understand their clinical needs, and address any scientific inquiries they may have. These will support their decision-making in patient care. •    What is the most difficult thing for you about being an MSL? We must be experts in the field for which we are responsible for. So continue to learn about diseases and keep uptake of new knowledge is a necessary but a challenging task for an MSL. •    What is the essential quality of an MSL for you? Good organizing skills, good presentation skills, and good communication skills. •    What motivates you to get up in the morning as an MSL? There are so many things that are worth learning and strength myself. And I have the chance to deal with them. So, I can always be better and stronger than yesterday. •    What is your most beautiful emotion experienced as an MSL? The most beautiful emotion I have experienced should be the sense of achievement. Especially when you earn the trust of the healthcare professionals through your professionalism. When the clinician proactively discusses the issues they face in real-world practice with you. •    Any words or advice for someone wanting to become an MSL? MSL is a challenging role because you will face and encounter many healthcare professionals and cross-function teams of different types. But if you like to learn and interact with people, don't hesitate to join. You will love it.       Know more about MSL

Pierre Fabre Laboratories wish you a very happy New Year 2025! Discover our e-card.

The script of the video :

An initiative supported by Pierre Fabre Laboratories in favor of scientific innovation in oncology. Villejuif, November 18, 2024 – On the occasion of the 150th anniversary of the birth of Professor Gustave Roussy and approaching the 100th anniversary of the Institute that bears his name, an international prize is being launched to reward scientific innovation in oncology. The Gustave Roussy Prize, endowed with €200,000 per year, aims to honor researchers whose discoveries have a significant impact on the care of cancer patients. Pierre Fabre Laboratories, as the founding patron, are supporting the creation of this prize. Éric Ducournau, CEO, expressed his pride in supporting this initiative: